Page last updated: 2024-08-24

tirofiban and Hemorrhage

tirofiban has been researched along with Hemorrhage in 112 studies

Research

Studies (112)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (8.04)18.2507
2000's46 (41.07)29.6817
2010's43 (38.39)24.3611
2020's14 (12.50)2.80

Authors

AuthorsStudies
Bian, Z; Cao, C; Ding, X; Feng, S; Kong, Y; Li, H; Li, Y; Li, Z; Oscar, B; Pan, C; Wang, W; Xie, Z; Zhao, L1
Dong, H; Hu, X; Lin, Y; Wang, W; Ye, J; Yu, B; Zhou, L; Zhou, Y1
Beaujeux, R; Chibbaro, S; Gheoca, R; Hasiu, A; Mangin, PH; Mihoc, D; Pop, R; Quenardelle, V; Severac, F; Simu, M; Tudor, R; Wolff, V1
Alyan, Ö; Er, A; Gürdal, A; Keskin, K; Kilci, H; Ser, ÖS; Sığırcı, S; Sümerkan, MÇ1
Esposito, G; Ettori, F; Ferlini, M; Lettieri, C; Marchese, A; Musumeci, G; Passamonti, E; Pierini, S; Rigattieri, S; Romano, M; Tarantini, G; Testa, L; Tiberti, G1
Chilbert, MR; Denny, O; Mills, K; Woodruff, AE1
Emani, SM; Piekarski, BL; Rogers, J; Thiagarajan, R; Zurakowski, D1
Adar, A; Akbay, E; Akıncı, S; Çoner, A; Müderrisoğlu, H1
Li, R; Tang, X; Zhang, T1
Gao, C; Han, X; Mitchell, MJ; Nie, G; Wang, C; Wang, K; Xu, J; Yan, N; Yang, C; Zhang, Y1
Ding, J; Huang, S; Ji, X; Lian, Y; Ma, Q; Ren, M; Song, H; Sun, C; Wang, L; Wang, Y; Wu, C; Wu, D; Xie, N; Zhao, W1
Adair, BD; Ahn, HS; Alonso, JL; Arnaout, MA; Hayes, V; Lin, SW; Poncz, M; van Agthoven, J; Xiong, JP; Yu, IS1
Huang, S; Li, X; Liang, C; Liu, C; Wang, H; Zhang, M1
Fu, Z; Gao, L; Liu, X; Wang, Z; Xu, C1
Degrauwe, S; Iglesias, JF; Laurencet, ME; Noble, S; Tessitore, E1
Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y1
Adina, Q; Bildirici, U; Celikyurt, U; Dervis, E; Ural, D; Yavuz, S1
Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y1
Chourdakis, E; Hahalis, G; Koniari, I; Kounis, NG; Patsouras, N; Roumeliotis, A; Soufras, G; Tsigkas, G1
Gao, D; Hu, S; Li, H; Li, M; Wang, H; Zhang, H; Zhu, J1
Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Levkau, B; Mourikis, P; Naguib, D; Pöhl, M; Polzin, A; Schulze, V; Wolff, G; Zako, S; Zeus, T1
Anderson, GL; Barsness, GW; Bell, MR; Mara, KC; Nei, SD; Osborn, JL; Ou, NN1
Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA1
Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S1
Gao, C; Hu, D; Li, M; Liu, H; Wang, X; Yang, H; Zhang, Y; Zhu, Z1
Chen, Y; Chi, Y; Liu, C; Song, L; Wang, J; Wang, S; Yan, H; Zhao, B; Zhao, H; Zhou, P1
Xie, Q; Zhang, J; Zhang, T; Zhu, J1
Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO1
Francis, PK; Gupta, PN; Shylaja, SV; Thomas, J1
Adiyaman, A; Giannitsis, E; Hamm, C; Hoorntje, JC; Schellings, DA; Suryapranata, H; Ten Berg, JM; Van't Hof, AW1
Ding, FH; Du, R; Hu, J; Liao, ML; Shen, WF; Wang, XL; Yang, ZK; Zhang, JS; Zhang, Q; Zhang, RY; Zhu, TQ1
Chen, J; Chen, S; Guo, J; Han, Y; Jiang, D; Jiang, T; Jing, Q; Li, J; Li, Y; Liang, Z; Liu, H; Stone, GW; Su, X; Wang, Y; Xu, B; Yang, P; Zang, H; Zhao, X; Zheng, Y1
Dondurmacı, E; Sağ Ertürk, F; Şarlı, B; Tok, A; Uğurlu, M1
Han, Y; Li, Y; Liang, Z; Liu, H; Ma, L; Stone, GW; Wang, D; Wang, J; Wang, S; Yang, L1
Huang, H; Ouyang, F; Peng, H; Yin, Y; Zeng, J; Zhou, X1
Chen, SL; Chen, YD; Chen, YG; Cheng, XS; Ge, JB; Han, YL; Jiang, TM; Li, JL; Li, Y; Liang, ZY; Liu, HW; Liu, ML; Ma, LK; Ma, YT; Wang, G; Wang, HY; Xie, Q; Yang, BS; Zhao, X; Zheng, XQ1
Fu, Q; Huang, YJ; Qiu, CR; Tao, ZQ; Wei, P; Yang, XJ; Zhang, Q; Zhang, YG; Zuo, XH1
Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD1
French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S1
Borklu, EB; Cinier, G; Eren, M; Hayiroglu, MI; Kaya, A; Keskin, M; Tatlisu, MA; Uzman, O1
Bao, D; Chen, Y; Cong, H; Ding, S; Han, Y; Jia, S; Jing, Q; Li, J; Li, L; Li, Y; Liang, Z; Liu, B; Liu, H; Wang, H; Zhao, X1
Chaudhary, HT1
Cao, Y; Ding, X; Gamariel, RR; Kong, Y; Li, ZY; Liu, TD; Liu, XD; Ming, X; Wang, CH; Xie, ZL; Zhao, Q1
Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q1
Cavusoglu, E; Lazar, J; Marmur, JD; Poludasu, S1
Zijlstra, F1
Chen, LL; Li, WW; Lin, YL; Luo, YK; Zheng, XC1
Jia, D; Li, Y; Nie, X; Yan, Z; Zhao, Y; Zhou, Y; Zhou, Z1
De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW1
Biondi-Zoccai, G; Bolognese, L; Briguori, C; Campo, G; Danzi, GB; Hamm, C; King, SB; Moliterno, DJ; Okmen, E; Saia, F; Tebaldi, M; ten Berg, J; Topol, EJ; Valgimigli, M; van't Hof, AW1
Briguori, C; Caccavale, M; D'Andrea, D; Focaccio, A; Golia, B; Librera, M; Ricciarelli, B; Tavano, D; Visconti, G1
Bates, ER; Chetcuti, S; Grossman, PM; Gurm, HS; Meier, P; Tamhane, U1
Agnelli, D; Al-Kayyali, S1
Juwana, YB; Ottervanger, JP; Suryapranata, H; van 't Hof, AW1
Doraiswamy, VA1
Tebaldi, M; Valgimigli, M1
Birhan Yilmaz, M; Caldir, V; Refiker Ege, M1
Dambrink, JH; Dill, T; Hamm, C; Hermanides, RS; Kolkman, E; Ottervanger, JP; Ten Berg, JM; van 't Hof, AW; van Houwelingen, G1
Moliterno, DJ1
Armstrong, PW; Bolognese, L; Braunwald, E; Califf, RM; Durand, E; Giugliano, RP; Harrington, RA; Hasselblad, V; Kong, DF; Moliterno, DJ; Newby, LK; Prabhakaran, D; Rasoul, S; Stone, GW; Théroux, P; Tricoci, P; Van de Werf, F; White, HD1
Eisenberg, MJ; Friedland, S; Shimony, A1
Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G1
Guo, J; Xi, Y; Xu, M1
Akpınar, TS; Besısık, SK; Elcioglu, OC; Ozkok, A; Sezer, M; Tufan, F; Umman, S1
Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Wang, X; Wang, Y; Wu, W; Xue, H; Yang, Z; Zhao, Y1
Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD1
Alpert, JS; Antman, EM; Beasley, JW; Braunwald, E; Califf, RM; Cheitlin, MD; Faxon, DP; Fuster, V; Gibbons, RJ; Gregoratos, G; Hiratzka, LF; Hochman, JS; Jacobs, AK; Jones, RH; Kereiakes, D; Kupersmith, J; Levin, TN; Pepine, CJ; Schaeffer, JW; Smith, EE; Smith, SC; Steward, DE; Theroux, P1
DiBattiste, PM; Jang, Ik; Januzzi, JL; Sabatine, MS; Servoss, SJ; Theroux, P; Wan, Y1
Tsakiris, DA1
Ali, A; Gardin, JM; Hashem, M; Kazmouz, G; Rosman, HS; Schrieber, TL1
Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Lorenz, DP; Marble, SJ; Murphy, SA; Pinto, DS1
Brown, DL1
Alemao, E; Bakhai, A; Ben-Joseph, R; Collinson, JR; Flather, MD; Itzler, R; Normand, C; Stevens, W1
Antman, EM; Bates, ER; Cohen, M; Every, NR; Ferguson, JJ; Harrington, RA; Pepine, CJ; Theroux, P1
Akin, Y; Biyikoglu, SF; Guray, U; Korkmaz, S; Yilmaz, MB1
Gill, DS; Ng, K; Ng, KS1
Ardissino, D; Brennan, DM; Buratti, S; Menozzi, A; Merlini, PA; Moliterno, DJ; Rossi, M; Topol, EJ1
Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD1
Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE1
Brouse, SD; Wiesehan, VG1
Graf, C; Nkoulou, R; Perrenoud, JJ; Trombert, V1
Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH1
DiBattiste, PM; Huynh, T; Pharand, C; Piazza, N; Snapinn, SM; Theroux, P; Wan, Y1
Berger, PB; Best, PJ; Chan, AW; DiBattiste, PM; Herrmann, HC; Kristensen, SD; Moliterno, DJ; Topol, EJ; White, J1
Chen, SM; Fang, CY; Fu, M; Guo, GB; Hsieh, YK; Wu, CJ; Yip, HK1
Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB1
Delgado, C; Fernández-Perez, GC; Rodríguez-Pérez, J; Vázquez, M; Vázquez-Lima, A; Velasco, M1
Banerjee, S; Chen, S; Ho, C; Labinaz, M; Martin, J; Mensinkai, S1
Anderson, KM; Coller, BS; Weisman, HF1
Anderson, HL; Edmunds, LH; Gikakis, N; Gorman, JH; Gould, RJ; Hiramatsu, Y; Marcinkiewicz, C; Niewiarowski, S1
Al-Mousa, EN; Arshad, MN; Campsey, M; Gandhi, R; Gibson, CM; Marble, SJ; Mattson, S; Mesley, R; Moynihan, JL; Murphy, S; Ryan, KA; Swanson, J1
Juran, NB1
Dyke, CM1
Tcheng, JE1
Califf, RM; Lincoff, AM; Topol, EJ1
Blankenship, JC; Dasgupta, H; Demko, SL; Frey, CM; Menapace, FJ; Wood, GC1
Jang, IK; Sabatine, MS1
Mak, KH; Moliterno, DJ1
Berkowitz, SD1
Vernon, SM1
Bertrand, M; Cohen, DJ; Cohen, EA; Demopoulos, L; DiBattiste, PM; Grines, CL; Herrmann, HC; Moliterno, DJ; Neumann, FJ; Powers, ER; Stone, GW; Topol, EJ1
Kurz, HI; Lasala, JM; Taniuchi, M1
Bertel, O; Genoni, M; Maloigne, M; Turina, M; Zeller, D1
Corno, A; Horisberger, J; Marty, B; Mueller, X; von Segesser, LK1
Becker, RC; Denier, D; Gouveia, W; Kimmelstiel, C; MacIsaac, DA; Miele, R; Phang, R; Rand, W; Rehman, A; Rhofiry, J1
Banaszewski, M; Konopka, A; Stepinska, J; Szajewski, T1
Kondo, K; Umemura, K1
DiBattiste, PM; Jang, IK; Januzzi, JL; Snapinn, SM; Theroux, P1
Cucchiara, BL; Hurst, RW; Liebeskind, DS; McGarvey, ML; Pollard, JR; Schwartz, ED1

Reviews

25 review(s) available for tirofiban and Hemorrhage

ArticleYear
Safety and Efficacy of Tirofiban in Acute Ischemic Stroke Patients Receiving Endovascular Treatment: A Meta-Analysis.
    Cerebrovascular diseases (Basel, Switzerland), 2020, Volume: 49, Issue:4

    Topics: Brain Ischemia; Endovascular Procedures; Hemorrhage; Humans; Patient Safety; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Time Factors; Tirofiban; Treatment Outcome

2020
+Ophitoxaemia and myocardial infarction--the issues during primary angioplasty: a review.
    BMJ case reports, 2014, Oct-23, Volume: 2014

    Topics: Angioplasty; Animals; Antivenins; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Bites; Snake Venoms; Snakes; Tirofiban; Tyrosine

2014
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
    European heart journal, 2010, Volume: 31, Issue:1

    Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Chemotherapy, Adjuvant; Hemorrhage; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Regression Analysis; Tirofiban; Tyrosine

2010
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Circulation. Cardiovascular interventions, 2009, Volume: 2, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2009
Tirofiban for myocardial infarction.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine

2010
Safety evaluation of tirofiban.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:5

    Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Double-Blind Method; Drug Resistance; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Multicenter Studies as Topic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine

2010
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Circulation. Cardiovascular quality and outcomes, 2011, Volume: 4, Issue:4

    Topics: Acetates; Acute Coronary Syndrome; Administration, Cutaneous; Angioplasty; Electrocardiography; Eptifibatide; Hemorrhage; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Tirofiban; Tyrosine

2011
Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
    The American journal of cardiology, 2011, Nov-01, Volume: 108, Issue:9

    Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Circulation; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine

2011
Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.
    Texas Heart Institute journal, 2012, Volume: 39, Issue:1

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Fatal Outcome; Female; Hemorrhage; Humans; Lung Diseases; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tirofiban; Tyrosine

2012
Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
    International journal of hematology, 2012, Volume: 96, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Hemorrhage; Humans; Male; Middle Aged; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Thrombocytopenia; Tirofiban; Tyrosine

2012
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Circulation, 2004, Aug-24, Volume: 110, Issue:8

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine

2004
Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
    The Canadian journal of cardiology, 2007, Volume: 23, Issue:12

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Bleeding Time; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Reoperation; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine

2007
The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
    Haemostasis, 1996, Volume: 26 Suppl 4

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Thrombosis; Tirofiban; Tyrosine

1996
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:3

    Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine

1999
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
    American heart journal, 1999, Volume: 138, Issue:4 Pt 2

    Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Catheterization, Peripheral; Coronary Disease; Coronary Thrombosis; Eptifibatide; Femoral Artery; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine

1999
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    American heart journal, 1999, Volume: 138, Issue:4 Pt 2

    Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Safety; Tirofiban; Tyrosine

1999
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
    American heart journal, 2000, Volume: 139, Issue:2 Pt 2

    Topics: Eptifibatide; Hemorrhage; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; Survival Rate; Thrombocytopenia; Tirofiban; Tyrosine

2000
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Journal of the American College of Cardiology, 2000, Volume: 35, Issue:5

    Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine

2000
Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
    American heart journal, 2000, Volume: 140, Issue:2

    Topics: Abciximab; Antibodies, Monoclonal; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Tirofiban; Tyrosine

2000
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    The American journal of medicine, 2000, Aug-15, Volume: 109, Issue:3

    Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine

2000
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes.
    Current cardiology reports, 1999, Volume: 1, Issue:3

    Topics: Acetates; Acute Disease; Eptifibatide; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Tirofiban; Tyrosine

1999
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Haemostasis, 2000, Volume: 30 Suppl 3

    Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration

2000
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
    Cardiology clinics, 2001, Volume: 19, Issue:2

    Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Nadroparin; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Thrombosis; Tirofiban; Transaminases; Tyrosine

2001
Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
    Perfusion, 2001, Volume: 16, Issue:5

    Topics: Abciximab; Ancrod; Antibodies, Monoclonal; Anticoagulants; Arginine; Cardiopulmonary Bypass; Chondroitin Sulfates; Cross Reactions; Dermatan Sulfate; Drug Combinations; Drug Hypersensitivity; Factor Xa Inhibitors; Hemodilution; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudin Therapy; Humans; Immunoglobulin Fab Fragments; Perfusion; Pipecolic Acids; Platelet Aggregation Inhibitors; Protamines; Sulfonamides; Thrombocytopenia; Thrombophilia; Thrombosis; Tirofiban; Tyrosine

2001
Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
    Clinical pharmacokinetics, 2002, Volume: 41, Issue:3

    Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine

2002

Trials

35 trial(s) available for tirofiban and Hemorrhage

ArticleYear
Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
    Coronary artery disease, 2022, 11-01, Volume: 33, Issue:7

    Topics: Anterior Wall Myocardial Infarction; Arrhythmias, Cardiac; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine

2022
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
    Kardiologia polska, 2017, Volume: 75, Issue:9

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine

2017
Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Clinical and experimental pharmacology & physiology, 2013, Volume: 40, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Drug Administration Schedule; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Complications; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine

2013
Impact of selective infarct-related artery infusion of tirofiban on myocardial reperfusion and bleeding complications in patients with acute myocardial infarction: the SUIT-AMI trial.
    The Journal of invasive cardiology, 2013, Volume: 25, Issue:8

    Topics: Aged; Cardiac Catheterization; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Prospective Studies; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine

2013
Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
    Journal of the American Heart Association, 2014, Nov-11, Volume: 3, Issue:6

    Topics: Aged; Area Under Curve; Biomarkers; Decision Support Techniques; Female; Hemorrhage; Humans; Length of Stay; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Patient Discharge; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2014
Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2015, Volume: 85 Suppl 1

    Topics: Aged; Biomarkers; Chi-Square Distribution; China; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Creatine Kinase, MB Form; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Prosthesis Design; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Up-Regulation

2015
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    JAMA, 2015, Apr-07, Volume: 313, Issue:13

    Topics: Aged; Antithrombins; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Tirofiban; Tyrosine

2015
The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2016, Volume: 87 Suppl 1

    Topics: Aged; Anticoagulants; Antithrombins; Chi-Square Distribution; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Emergency Treatment; Female; Hemorrhage; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Protective Factors; Recombinant Proteins; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2016
Clinical effects of treatment with Tirofiban on patients with high-risk NSTE-ACS after PCI.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:7

    Topics: Acute Coronary Syndrome; Adult; Aged; Creatine Kinase, MB Form; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine

2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    American heart journal, 2016, Volume: 177

    Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine

2016
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:5

    Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2016
Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Jun-01, Volume: 89, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cardiac Catheterization; China; Emergencies; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radial Artery; Recombinant Proteins; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Warfarin; Young Adult

2017
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:10

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Vessels; Drug Administration Routes; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Tirofiban; Tyrosine

2008
Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome.
    Acta pharmacologica Sinica, 2009, Volume: 30, Issue:5

    Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine

2009
Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.
    Clinical cardiology, 2009, Volume: 32, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Heart Diseases; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Thrombocytopenia; Time Factors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine

2009
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine

2009
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
    The American journal of cardiology, 2009, Nov-01, Volume: 104, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Retreatment; Thrombocytopenia; Tirofiban; Tyrosine

2009
Risk of bleeding after prehospital administration of high dose tirofiban for ST elevation myocardial infarction.
    International journal of cardiology, 2012, May-17, Volume: 157, Issue:1

    Topics: Aged; Emergency Medical Services; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors; Single-Blind Method; Tirofiban; Tyrosine

2012
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011, Jun-01, Volume: 77, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States

2011
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    The Journal of invasive cardiology, 2012, Volume: 24, Issue:3

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Retrospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine

2012
Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
    Cardiovascular therapeutics, 2013, Volume: 31, Issue:4

    Topics: Acute Coronary Syndrome; Administration, Intravenous; Aged; Chi-Square Distribution; China; Coronary Angiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2013
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
    American heart journal, 2002, Volume: 144, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine

2002
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
    International journal of cardiology, 2003, Volume: 91, Issue:2-3

    Topics: Aged; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Patient Admission; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Syndrome; Tirofiban; Treatment Outcome; Tyrosine; United Kingdom

2003
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    American heart journal, 2003, Volume: 146, Issue:4

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine

2003
Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Circulation, 2004, May-11, Volume: 109, Issue:18

    Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Transfusion; Combined Modality Therapy; Coronary Stenosis; Double-Blind Method; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Stents; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine

2004
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    JAMA, 2004, Jul-07, Volume: 292, Issue:1

    Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine

2004
Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
    Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:2

    Topics: Acute Disease; Aged; Coronary Disease; Dalteparin; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine

2005
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
    American heart journal, 2005, Volume: 149, Issue:5

    Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Stenosis; Creatinine; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Myocardial Ischemia; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Tirofiban; Treatment Outcome; Tyrosine

2005
Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention.
    Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:5

    Topics: Aged; Angiography; Angioplasty, Balloon, Coronary; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Recurrence; Tirofiban; Treatment Outcome; Tyrosine

2006
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban
    Circulation, 1997, Sep-02, Volume: 96, Issue:5

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Thrombosis; Double-Blind Method; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIb-IX Complex; Postoperative Complications; Retreatment; Time Factors; Tirofiban; Tyrosine

1997
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    The New England journal of medicine, 1998, 05-21, Volume: 338, Issue:21

    Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Tirofiban; Tyrosine

1998
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:3

    Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine

1999
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    The New England journal of medicine, 2001, Jun-21, Volume: 344, Issue:25

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Tirofiban; Tyrosine

2001
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
    Circulation, 2001, Jul-31, Volume: 104, Issue:5

    Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; Exanthema; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Neutropenia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine

2001
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS
    Circulation, 2002, May-21, Volume: 105, Issue:20

    Topics: Acute Disease; Aged; Coronary Artery Disease; Creatinine; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Assessment; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine

2002

Other Studies

53 other study(ies) available for tirofiban and Hemorrhage

ArticleYear
Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.
    European journal of medicinal chemistry, 2017, Jan-05, Volume: 125

    Topics: Drug Design; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propionates; Thrombosis

2017
Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Aged; China; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome

2021
Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy.
    Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2023, Volume: 29, Issue:3

    Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; Thrombectomy; Tirofiban; Treatment Outcome

2023
In-Hospital Bleeding in Elderly Patients With Acute Coronary Syndrome: Are Potent Antiplatelet Agents Safe?
    Angiology, 2022, Volume: 73, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Female; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Tirofiban; Treatment Outcome

2022
Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry.
    Journal of interventional cardiology, 2022, Volume: 2022

    Topics: Aged; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Reperfusion; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine

2022
Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    Journal of cardiovascular pharmacology, 2022, 07-01, Volume: 80, Issue:1

    Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome

2022
Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2022, 09-01, Volume: 23, Issue:9

    Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Cohort Studies; Fibrinolytic Agents; Hemorrhage; Humans; Integrin alpha2; Integrin beta3; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Thrombosis; Tirofiban; Treatment Outcome

2022
In-Hospital Bleeding and Mortality in Acute Coronary Syndrome Patients Treated with Tirofiban and Potent P2Y12 Inhibitors.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2022, Volume: 50, Issue:5

    Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Tirofiban; Treatment Outcome

2022
Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents.
    Circulation research, 2023, 02-03, Volume: 132, Issue:3

    Topics: Animals; Blood Platelets; Hemorrhage; Mice; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Tirofiban

2023
Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome After Intravenous Thrombolysis.
    Stroke, 2019, Volume: 50, Issue:12

    Topics: Aged; Disease Progression; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Mortality; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Thrombolytic Therapy; Tirofiban; Tissue Plasminogen Activator; Treatment Outcome

2019
Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis.
    Nature communications, 2020, 01-21, Volume: 11, Issue:1

    Topics: Animals; Blood Coagulation; Disease Models, Animal; Drug Design; Gene Knock-In Techniques; Healthy Volunteers; Hemorrhage; Humans; K562 Cells; Male; Mice; Mice, Transgenic; Peptides; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Structure-Activity Relationship; Thrombosis; Tirofiban; von Willebrand Factor

2020
Effects of Oral Antiplatelet Agents and Tirofiban on Functional Outcomes of Patients with Non-Disabling Minor Acute Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:8

    Topics: Administration, Intravenous; Administration, Oral; Aged; Brain Ischemia; Disability Evaluation; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recovery of Function; Retrospective Studies; Risk Factors; Stroke; Time Factors; Tirofiban; Treatment Outcome

2020
Walking on a thin line between potent platelet inhibition for myocardial infarction and risk of hemorrhagic complications. Tirofiban induced subconjunctival hemorrhage.
    Cardiology journal, 2021, Volume: 28, Issue:2

    Topics: Adult; Blood Platelets; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine; Walking

2021
Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients.
    Journal of cardiovascular pharmacology, 2021, 09-01, Volume: 78, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Dual Anti-Platelet Therapy; Female; Functional Status; Hemorrhage; Humans; Infusions, Intravenous; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Recovery of Function; Retrospective Studies; Time Factors; Tirofiban; Treatment Outcome

2021
Early Thrombosuction and Tirofiban Use in Knee and Below-Knee Arterial Thrombosis.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Apr-30, Volume: 23

    Topics: Aged; Aged, 80 and over; Arteries; Embolism; Female; Hemorrhage; Humans; Knee Joint; Leg; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombectomy; Thromboembolism; Tirofiban; Treatment Outcome; Tyrosine

2017
Perioperative Management of Dual Antiplatelet Therapy.
    Journal of cardiothoracic and vascular anesthesia, 2018, Volume: 32, Issue:3

    Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Tirofiban; Tyrosine

2018
Effect of intra-coronary administration of tirofiban through aspiration catheter on patients over 60 years with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Medicine, 2018, Volume: 97, Issue:21

    Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon, Coronary; Catheters; Drug Administration Routes; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardium; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stroke; Tirofiban; Treatment Outcome; Tyrosine

2018
Safety and efficacy of Tirofiban in STEMI-patients.
    International journal of cardiology, 2019, Jan-01, Volume: 274

    Topics: Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Germany; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome

2019
Comparison of In-Hospital Bleeding and Cardiovascular Events with High-Dose Bolus Tirofiban and Shortened Infusion to Short-Duration Eptifibatide as Adjunctive Therapy for Percutaneous Coronary Intervention.
    The American journal of cardiology, 2019, 01-01, Volume: 123, Issue:1

    Topics: Aged; Eptifibatide; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Time Factors; Tirofiban; Treatment Outcome

2019
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
    Cardiovascular revascularization medicine : including molecular interventions, 2019, Volume: 20, Issue:9

    Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome

2019
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
    Kardiologiia, 2013, Volume: 53, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Monitoring; Electrocardiography; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine

2013
Effects of upstream administration of tirofiban before percutaneous coronary intervention on spontaneous reperfusion and clinical outcomes in acute ST-segment elevation myocardial infarction.
    Angiology, 2015, Volume: 66, Issue:1

    Topics: Aged; Chi-Square Distribution; Combined Modality Therapy; Coronary Circulation; Disease-Free Survival; Drug Administration Schedule; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2015
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:1

    Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrhage; Humans; Italy; Myocardial Ischemia; Peptides; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Societies, Medical; Stents; Surgical Procedures, Operative; Thoracic Surgery; Ticlopidine; Tirofiban; Tyrosine

2014
A misleading diagnosis in acute coronary syndrome: tirofiban-induced alveolar hemorrhage.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015, Volume: 43, Issue:8

    Topics: Acute Coronary Syndrome; Acute Lung Injury; Adult; Diagnostic Errors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Tirofiban; Tyrosine

2015
Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia.
    International journal of cardiology, 2016, Mar-01, Volume: 206

    Topics: Aged; Coronary Occlusion; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Thrombocytopenia; Tirofiban; Tyrosine

2016
[A large-scale, multicenter, retrospective study on efficacy of bivalirudin use during peri-percutaneous coronary intervention period for Chinese patients with coronary heart disease].
    Zhonghua xin xue guan bing za zhi, 2016, Volume: 44, Issue:2

    Topics: Aged; China; Coronary Disease; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; Stroke; Tirofiban; Tyrosine

2016
The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
    Coronary artery disease, 2016, Volume: 27, Issue:7

    Topics: Aged; Cause of Death; Coronary Thrombosis; Female; Hemorrhage; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2016
In-Silico Analysis of Amotosalen Hydrochloride Binding to CD-61 of Platelets.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2016, Volume: 26, Issue:11

    Topics: Bleeding Time; Blood Platelets; Computer Simulation; Furocoumarins; Hemorrhage; Humans; Photosensitizing Agents; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine

2016
A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin
    BioMed research international, 2016, Volume: 2016

    Topics: Abciximab; Animals; Antibodies, Monoclonal; Cardiovascular Diseases; Disease Models, Animal; Eptifibatide; Fibrinogen; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Integrin alpha2; Integrin beta3; Mice; Naphthalenes; Peptides; Platelet Aggregation; Rats; Thrombocytopenia; Thrombosis; Tirofiban; Tyrosine

2016
Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Feb-01, Volume: 73, Issue:2

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2009
The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Feb-01, Volume: 73, Issue:2

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2009
Alveolar hemorrhage following tirofiban treatment. A misleading diagnosis.
    Revista espanola de cardiologia, 2010, Volume: 63, Issue:3

    Topics: Aged; Diagnostic Errors; Female; Hemorrhage; Humans; Lung Diseases; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Tirofiban; Tyrosine

2010
Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring
    Circulation, 2010, Mar-09, Volume: 121, Issue:9

    Topics: Anticoagulants; Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Double-Blind Method; Drug Resistance; Elective Surgical Procedures; Hemorrhage; Heparin; Humans; Myocardial Revascularization; Patient Selection; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Research Design; Thromboembolism; Ticlopidine; Tirofiban; Tyrosine

2010
Alveolar hemorrhage following tirofiban treatment. A misleading diagnosis.
    Revista espanola de cardiologia, 2010, Volume: 63, Issue:12

    Topics: Hemorrhage; Humans; Lung Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Alveoli; Pulmonary Wedge Pressure; Tirofiban; Tyrosine

2010
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
    Circulation, 2002, Oct-01, Volume: 106, Issue:14

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clopidogrel; Disease Management; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Health Behavior; Hemorrhage; Humans; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine

2002
Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.
    The American journal of cardiology, 2003, Feb-15, Volume: 91, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Linear Models; Logistic Models; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Factors; Safety; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2003
[New antiaggregants and their importance for the practitioner].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Ticlopidine; Tirofiban; Tyrosine

2003
Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage.
    The Journal of invasive cardiology, 2003, Volume: 15, Issue:4

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Lung Diseases; Male; Michigan; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Wedge Pressure; Tirofiban; Treatment Failure; Tyrosine; Ventricular Pressure

2003
Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).
    The American journal of cardiology, 2003, Apr-15, Volume: 91, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Blood Coagulation Tests; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Tirofiban; Tyrosine

2003
Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
    Heart (British Cardiac Society), 2003, Volume: 89, Issue:5

    Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Death, Sudden; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Tyrosine

2003
Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication.
    International journal of cardiology, 2004, Volume: 93, Issue:1

    Topics: Coronary Stenosis; Fatal Outcome; Female; Hemorrhage; Humans; Lung Diseases; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine

2004
Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.
    Heart (British Cardiac Society), 2004, Volume: 90, Issue:3

    Topics: Angina, Unstable; Diagnostic Errors; Fatal Outcome; Hemorrhage; Humans; Lung Diseases; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Edema; Radiography; Tirofiban; Tyrosine

2004
Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:11

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Hospitals, Veterans; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Regression Analysis; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine

2004
Safety of tirofiban therapy in very old patients with acute coronary syndrome or non-Q-wave myocardial infarction.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:1

    Topics: Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine

2005
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
    International journal of cardiology, 2005, Apr-08, Volume: 100, Issue:1

    Topics: Aged; Angina, Unstable; Anticoagulants; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Syndrome; Tirofiban; Tyrosine

2005
Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
    Circulation, 2006, Sep-26, Volume: 114, Issue:13

    Topics: Acute Disease; Adult; Angina, Unstable; Blood Transfusion; Cerebral Hemorrhage; Creatinine; Disease Susceptibility; Dose-Response Relationship, Drug; Eptifibatide; Glomerular Filtration Rate; Hemorrhage; Hemorrhagic Disorders; Humans; Kidney Diseases; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Registries; Sex Characteristics; Tirofiban; Tyrosine

2006
Pulmonary hemorrhage in a patient with acute coronary syndrome.
    AJR. American journal of roentgenology, 2007, Volume: 189, Issue:3

    Topics: Aged; Angina, Unstable; Hemorrhage; Humans; Lung Diseases; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Tirofiban; Tyrosine

2007
Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons.
    The Journal of thoracic and cardiovascular surgery, 1997, Volume: 113, Issue:1

    Topics: Animals; Bleeding Time; Cardiopulmonary Bypass; Hemodynamics; Hemorrhage; Heparin; Papio; Platelet Aggregation Inhibitors; Platelet Count; Postoperative Complications; Tirofiban; Tyrosine

1997
Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
    The Medical letter on drugs and therapeutics, 1998, Sep-11, Volume: 40, Issue:1035

    Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Premedication; Syndrome; Tirofiban; Tyrosine

1998
Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery.
    The Journal of thoracic and cardiovascular surgery, 2001, Volume: 122, Issue:3

    Topics: Blood Coagulation; Blood Transfusion; Coronary Disease; Drug Administration Schedule; Drug Monitoring; Emergencies; Hemorrhage; Humans; Infusions, Intravenous; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2001
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Journal of thrombosis and thrombolysis, 2001, Volume: 11, Issue:3

    Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Creatine Kinase; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Retrospective Studies; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine

2001
Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
    Thrombosis and haemostasis, 2002, Volume: 87, Issue:2

    Topics: Anticoagulants; Coronary Stenosis; Drug Therapy, Combination; Enoxaparin; Factor VII; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Stents; Tirofiban; Tyrosine; Vascular Patency

2002
Vertebrobasilar thrombolysis with intravenous tirofiban: case report.
    Journal of thrombosis and thrombolysis, 2002, Volume: 13, Issue:2

    Topics: Aged; Arterial Occlusive Diseases; Fibrinolytic Agents; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine; Vertebrobasilar Insufficiency

2002